Over the past 20 years, Dr. Zhao performed over 1,200 vascular interventions, ablations, and other interventional procedures for cancer patients care annually, and provided consultations to approximately 4,000 outpatients per year.
As the principal investigator, Dr. Zhao host multiple projects funded by the National Natural Science Foundation and participated in projects under the National Key Research and Development Program of China, along with various international and domestic clinical trials. Dr. Zhao published 130 papers independently and collaboratively, including 70 papers as first or corresponding author. Among these, 53 first/corresponding-author papers were published in international SCI-indexed journals, such as Journal of Clinical Oncology, Gut, Journal of Hepatology, Nature Communications, Radiology, American Journal of Gastroenterology, International Journal of Surgery, Journal for Immunotherapy of Cancer, Liver Cancer, and European Journal of Cancer. Dr. Zhao pioneered the use of the mFOLFOX regimen for hepatic arterial infusion chemotherapy (HAIC) in advanced Hepatocellular Carcinoma (HCC) and delivered an oral presentation on this at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The HAIC-FOLFOX regimen was incorporated into the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer and the China Liver Cancer Staging (CNLC), published by the National Health Commission and the Chinese Society of Clinical Oncology (CSCO). Dr. Zhao led the development of the Chinese Expert Consensus on HAIC for HCC (Hepatology International, 2024). Dr. Zhao participated in the development and revision of several key guidelines and consensus, including the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer led by the National Health Commission and the CSCO, the TACE Clinical Practice Consensus—ISMIO International HCC Expert Collaboration Group (2021), and the Clinical Practice Guidelines for TACE in Chinese HCC.

Awards and Honors
1.First Prize of the Guangdong Science and Technology Progress Award
2.First Prize of the Chinese Medical Science and Technology Progress Award
3.Medical Scientist at Sun Yat-sen University Cancer Center
4.Expert in the Expert Pool of China’s Ministry of Science and Technology
5.Most Influential Young and Middle-aged Doctor in Guangdong Province
6.Best Doctor in Guangzhou

Minimally invasive interventional therapy, systemic therapy, and comprehensive management of liver cancers; image-guided minimally invasive therapies (intervention, ablation) for various solid tumors, along with multi-disciplinary treatment. 

1.Visiting scholar (Research on Tumor Immunology and Translational Medicine), Brigham and Women’s Hospital, Harvard Medical School, April 2011 to September 2013
2.Visiting scholar (Clinical training for liver cancer), Barcelona Clinical Liver Cancer Research Center, Spain, April 2008 to September 2008
3.Doctor’s degree (Oncology), Sun Yat-sen University, China, September 2002 to December 2006
4.Master’s degree (Oncology), Sun Yat-sen University of Medical Sciences, China, September 1997 to July 2000
5.Bachelor’s degree (Clinical medicine), Bangbu Medical University, China, September 1988 to July 1993

1. Zhang YM, Wu XT, Yi JZ, Xu J, Zhang YN, Lyu N, Zhao Ming (Corresponding Author). Matching adjusted indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocelular Carcinoma. Liver Cancer. 2025 Apr 22:1-18. Full text available at: https://maipdf.cn/file/at686b53aa45431/pdf

2. Chen QF, Chen S, Yi JZ, Wang JL, Zhong SX, Jiang XY, Hu Y, Tan GJ, Xu J, Lyu N, Zhao Ming (Corresponding Author). Recommended Ten Years' Follow-Up Strategy for Small Hepatocellular Carcinoma after Radiofrequency Ablation: A Cost-Effectiveness Evaluation. American J Gastroenterology. 2024-10-01;119(10):2052-2060. Full text available at: https://maipdf.cn/file/at67f4ef63c998c/pdf

3. He M, Liu Y, Chen S, Deng H, Feng C, Qiao S, Chen Q, Hu Y, Chen H, Wang X, Jiang X, Xia X, Zhao Ming (Co-corresponding Author), Lyu N. Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma. Nature Communications. 2024 Feb 26;15(1):1754. Full text available at: https://maipdf.cn/file/at67f4efb3c9ab0/pdf

4. Zhao Ming (Corresponding Author), Guo Z, Zou YH, Li X, Yan ZP, Chen MS, Fan WJ, Li HL, Yang JJ, Chen XM, Xu LF, Zhang YW, Zhu KS, Sun JH, Li JP, Jin Y, Yu HP, Duan F, Xiong B, Yin GW, Lin HL, Ma YL, Wang HM, Gu SZ, Si TG, Wang XD, Zhao C, Yu WC, Guo JH, Zhai J, Huang YH, Wang WY, Lin HF, Gu YK, Chen JZ, Wang JP, Zhang YM, Yi JZ, Lyu N. Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. Hepatology International.2024 Feb;18(1):4-31. Full text available at: https://maipdf.cn/file/at67f4ec387b241/pdf

5. Chen QF, Lyu N, Wang X, Jiang XY, Hu Y, Chen S, Zhong SX, Huang ZL, Chen M, Zhao Ming (Corresponding Author). Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial. International Journal of Surgery. 2023 Sep 4;109(12):3929–3939. Full text available at: https://maipdf.cn/file/at67f4ec8dbaadd/pdf

6. Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao Ming (Corresponding Author). Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). Journal Clinical Oncology. 2022 Feb 10;40(5):468-480. Full text available at: https://maipdf.cn/file/at67f4efe77e74a/pdf

7. Lyu N, Yi JZ, Zhao Ming (Corresponding Author). Immunotherapy in older patients with hepatocellular carcinoma. European Journal of Cancer. 2022 Feb; 162: 76-98. Full text available at: https://maipdf.cn/file/at67f4f14888350/pdf

8. Deng HJ, Anna Kan, Lyu N, HE M, Huang X, Qiao S, Li SL, LU WH, Xie QK, Chen HM, Lai JF, Chen QF, Jiang XY, Liu S, Zhang ZF, Zhao Ming (Corresponding Author).  Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. Journal of Immunotherapy Cancer 2021;9:e002305. Full text available at: https://maipdf.cn/file/at67f4f1dae0625/pdf

9. Deng HJ,  Kan A, Lyu,Mu LW,  HanY, Liu LZ,  Zhang YY,  Duan YF,  Liao SY, Li SL, Xie QK, Gao TX,  Li YR, Zhang ZF, Zhao Ming (Corresponding Author). Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer; 2020 9:338-357. Full text available at: https://maipdf.cn/file/at67f51176eb761/pdf

10. Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y, Zhang Z, Zheng L, Deng H, Li S, Xie Q, Guo R, Shi M, Xu L, Cai X, Wu P, Zhao Ming (Corresponding Author). Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. Journal of Hepatology. 2018 Jul;69(1):60-69. Full text available at: https://maipdf.cn/file/at67f512ee2200e/pdf

11. Lyu N, Lin YE, Kong YN,Zhang ZF,Liu LZ, Zheng L, Mu LW, Wang JP, Li XS,Pan T, Xie QK, Liu YR, Lin AH, Wu PH, Zhao Ming (Corresponding Author). FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/ leucovorin for advanced hepatocellular carcinoma. Gut. 2017 February Vol 67 No 2 395-397. Full text available at: https://maipdf.cn/file/at67f5153f425ac/pdf

12. Pan T, Xie QK, Lv N, Li XS, Mu LW, Wu PH, Zhao Ming (Corresponding Author).  Percutaneous CT-guided Radiofrequency Ablation for Lymph Node Oligometastases from Hepatocellular Carcinoma: A Propensity Score-matching Analysis. Radiology. 2017 Jan;282(1):259-270. Full text available at: https://maipdf.cn/file/at67f51572dd85d/pdf

Updated by International Office, Sun Yat-sen University Cancer Center